Differential effects of PPARγ activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo

Journal of Gastroenterology

Volumn 44, Issue 9, 2009, Pages 919-929

  Al Taie, Oliver H ^a   Graf, Tilmann ^b   Illert, Bertram ^b   Katzenberger, Tiemo ^b   Mörk, Hubert ^c   Kraus, Michael R ^b   Barthelmes, Hans U ^d   Scheurlen, Michael ^a   Seufert, Jochen ^e  

^a KLINIKUM ASCHAFFENBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Kreiskrankenhaus Nagold ^*  (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Apoptosis; Barrett's carcinoma; Cell proliferation; PPAR ; Thiazolidinediones

Indexed keywords

GLUCOSE; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; FEMALE; GENE ACTIVATION; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DRUG EFFECT; ESOPHAGUS TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BARRETT ESOPHAGUS; CELL LINE, TUMOR; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 70349652053     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0086-y     Document Type: Article

References (47)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, et al. The nuclear receptor superfamily: The second decade. Cell. 1995;83:835-9.
2. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature. 1992;355:446-9.
3. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 1997;386:407-10.
4. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-12.
5. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995;83:813-9.
6. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Proc Natl Acad Sci USA. 1997;94:4318-23.
7. Thompson EA. PPARγ physiology and pathology in gastrointestinal epithelial cells. Mol Cells. 2007;24:167-76.
8. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR) gamma: Adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 1994;135:798-800.
9. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA. 1997;94:237-41.
10. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998;1:465-70.
11. Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 1998;95:8806-11.
12. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med. 1998;4:1046-52.
13. Brockman JA, Gupta RA, Dubois RN. Activation of PPAR gamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology. 1998;115:1049-55.
14. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58:3344-52.
15. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human pancreatic carcinoma cells. Cancer Res. 2000;60:5558-64.
16. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y. Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 1999;455:135-9.
17. Itami A, Watanabe G, Shimada Y, Hashimoto Y, Kawamura J, Kato M, et al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer. 2001;94:370-6.
18. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPAR gamma agonists. Br J Cancer. 2000;83:1394-400.
19. Butler R, Mitchell SH, Tindall DJ, Young CY. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12, 14-prostaglandin J2. Cell Growth Differ. 2000;11:49-61.
20. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Weber JL, Russell SE. Barrett's oesophagus: Microsatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence. Genes Chromosomes Cancer. 1998;21:49-60.
21. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients. Diabetes. 1997;46:1319-27.
22. Illert B, Otto C, Thiede A, Timmermann W, Braendlein S. Detection of disseminated tumor cells in nude mice with human gastric cancer. Optimization of a metastasizing human gastric cancer model in nude mice. Clin Exp Metastasis. 2003;20:549-54.
23. Frantz S, Hu K, Widder J, Bayer B, Witzel CC, Schmidt I, et al. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol. 2004;141:9-14.
24. Nakashiro K, Begum NM, Uchida D, Kawamata H, Shintani S, Sato M, et al. Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma. Oral Oncol. 2003;39:855-61.
25. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol. 2002;2:748-59.
26. Tselepis C, Perry I, Dawson C, Hardy R, Darnton SJ, McConkey C, et al. Tumour necrosis factor-alpha in Barrett's oesophagus: A potential novel mechanism of action. Oncogene. 2002;21:6071-81.
27. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, et al. NF-kappaB activation in esophageal adenocarcinoma: Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239:491-500.
28. Han C, Demetris AJ, Michalopoulos GK, Zhan Q, Shelhamer JH, Wu T. PPAR gamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. Hepatology. 2003;38:167-77.
29. Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, et al. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology. 2001;33:1087-97.
30. Altiok S, Xu M, Spiegelman BM. PPAR gamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 1997;11:1987-98.
31. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1-> S transition in vascular smooth muscle cells. J Biol Chem. 2000;275:22435-41.
32. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology. 2003;124:361-7.
33. Pighetti GM, Novosad W, Nicholson C, Hitt DC, Hansens C, Hollingsworth AB, et al. Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands. Anticancer Res. 2001;21:825-9.
34. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, et al. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 1999;59:5671-3.
35. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+mice. Nat Med. 1998;4:1053-7.
36. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, et al. Activators of the nuclear receptor PPAR gamma enhance colon polyp formation. Nat Med. 1998;4:1058-61.
37. Hanahan D, Weinberg RA, et al. The hallmarks of cancer. Cell. 2000;100:57-70.
38. Clay CE, Namen AM, Atsumi G, Trimboli AJ, Fonteh AN, High KP, et al. Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Investig Med. 2001;49:413-20.
39. Burgermeister E, Seger R. MAPK kinases as nucleocytoplasmic shuttles of PPATγ. Cell Cycle. 2007;6:1539-2007.
40. Palakurthi SS, Aktas H, Grubissisch LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor g and mediated by inhibition of translation initiation. Cancer Res. 2001;61:6213-8.
41. Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A, et al. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer. 2003;98:2251-6.
42. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci USA. 2000;97:10990-5.
43. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: A phase II study. Breast Cancer Res Treat. 2003;79:391-7.
44. Yee LD, Williams N, Wen P, Young DC, Lester J, Johnson MV, et al. Pilot study of rosiglitazone therapy in women with breast cancer: Effects of short term therapy on tumor tissue and serum markers. Clin Cancer Res. 2007;13:246-52.
45. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer. 2003;89:1409-12.
46. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, et al. A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 2002;8:395-9.
47. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004;101:1569-74.